Presentation is loading. Please wait.

Presentation is loading. Please wait.

Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With Renal Dysfunction  Masatoshi Ishigami,

Similar presentations


Presentation on theme: "Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With Renal Dysfunction  Masatoshi Ishigami,"— Presentation transcript:

1 Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With Renal Dysfunction  Masatoshi Ishigami, Kazuhiko Hayashi, Takashi Honda, Teiji Kuzuya, Yoji Ishizu, Tetsuya Ishikawa, Isao Nakano, Fumihiro Urano, Takashi Kumada, Kentaro Yoshioka, Hidemi Goto, Yoshiki Hirooka  Clinical Gastroenterology and Hepatology  Volume 15, Issue 5, Pages (May 2017) DOI: /j.cgh Copyright © 2017 AGA Institute Terms and Conditions

2 Figure 1 Rate of liver injury during treatment in patients with or without renal dysfunction according to the grade of liver injury. Grade 0, <1.25 times upper limited of normal (ULN); grade 1, ≥1.25 to <2.5 times ULN; grade 2, ≥2.5 to <5 times ULN; grade 3, ≥5 to <10 times ULN; grade 4, ≥10 times ULN. Liver injury according to grade in patients with an eGFR of (A) ≥50 mL/min, (B) 30–49 mL/min, (C) <30 mL/min, and (D) <50 mL/min is shown. Statistical value (P < .001) is based on the comparison between patients with eGFR of ≥50 mL/min (A) and those with eGFR <50 mL/min (D). Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh ) Copyright © 2017 AGA Institute Terms and Conditions


Download ppt "Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With Renal Dysfunction  Masatoshi Ishigami,"

Similar presentations


Ads by Google